Hims & Hers appoints former FDA official Deb Autor as inaugural policy chief
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 17 2025
0mins
Should l Buy HIMS?
Source: Reuters
New Appointment: Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, leveraging her extensive experience in regulatory operations and policy.
Regulatory Engagement: Autor's role will focus on enhancing the company's engagement with regulators and policymakers, especially following recent scrutiny from the FDA regarding misleading marketing practices.
Board Membership: In addition to her new role, Autor will continue to serve on the Hims & Hers board, where she has been a member since last year.
Product Strategy Shift: The company has adapted its product offerings by selling personalized versions of semaglutide, in response to government restrictions on the mass production of copies of weight-loss drugs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 42.88 USD with a low forecast of 29.00 USD and a high forecast of 85.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 23.020
Low
29.00
Averages
42.88
High
85.00
Current: 23.020
Low
29.00
Averages
42.88
High
85.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bank of America Lowers Hims & Hers Price Target
- Price Target Reduction: Bank of America has lowered its price target for Hims & Hers, primarily due to FDA uncertainty and slowing GLP-1 sales, indicating market concerns regarding the company's future performance.
- Revenue Risk Warning: Analysts have highlighted that increasing uncertainty around FDA approvals may pose downside risks to Hims & Hers' revenue and profits, potentially impacting investor confidence.
- Uncertain Profit Outlook: Ahead of the upcoming earnings report, Bank of America expresses concerns over Hims & Hers' profit outlook, suggesting that the current market environment may lead to performance falling short of expectations.
- Market Reaction Anticipation: Given the price target reduction and warnings about profit risks, the market may react negatively to Hims & Hers' stock performance, prompting investors to carefully assess its future prospects.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
Hims & Hers Health Stock Faces Pressure Amid Regulatory Concerns
- Price Forecast Cut: BofA Securities has lowered the price target for Hims & Hers Health from $26 to $21 while maintaining an Underperform rating, indicating that the growing risks associated with GLP-1 sales could lead to a decline in future EBITDA multiples to 18.5x, highlighting increased market pressure on the company.
- Product Withdrawal Impact: Hims & Hers has decided to cease offering its compounded Semaglutide pill following accusations from Novo Nordisk of unlawful mass marketing of an unapproved drug, which may diminish the company's competitiveness in the weight loss market and negatively affect future revenues.
- Revenue Outlook Downgrade: BofA estimates that Hims & Hers will generate $825-$850 million in injectable GLP-1 sales for fiscal 2025 at approximately 10% EBITDA margins, while the management has narrowed its fiscal 2025 revenue outlook to a range of $2.335 billion to $2.355 billion, reflecting market concerns over its performance.
- Significant Stock Volatility: As of Monday, Hims shares are down 18.77% at $18.70, indicating investor anxiety regarding the company's future performance, particularly in light of potential FDA restrictions on GLP-1 active pharmaceutical ingredients, leading to heightened market caution.
See More
Hims & Hers Shares Plunge to New 52-Week Lows Amid Legal and Regulatory Challenges
- Stock Plunge: Hims & Hers shares fell to new 52-week lows on Monday, dropping 20.10% to $18.39, indicating severe market concerns regarding the company's growth prospects.
- Regulatory Pressure: The company announced it would cease sales of its compounded oral semaglutide pill just 48 hours after launch, highlighting significant challenges in its market strategy under intense FDA and DOJ scrutiny.
- Patent Lawsuit: Novo Nordisk filed a patent infringement lawsuit on Monday, exacerbating Hims & Hers' legal troubles and raising doubts among investors about the profitability of its new product line.
- Surge in Trading Volume: On Monday, Hims & Hers experienced trading volume exceeding four times its average, reflecting strong investor reactions to the uncertainty surrounding the company's future, leading to significant sell-offs.
See More
Novo Nordisk Stock Rebounds as Hims Abandons Copycat Drug Plans
- Stock Volatility: Novo Nordisk's shares plummeted 27% last week due to Hims' plan to sell a $49 copy of Wegovy, but rebounded 3% after Hims announced it would not proceed with the sale, indicating a restoration of market confidence in Novo's products.
- Legal Threat: Novo Nordisk expressed strong dissatisfaction with Hims' copycat plans and threatened to sue for patent infringement last Friday, demonstrating the company's firm stance on protecting its intellectual property, which could impact Hims' competitive position in the market.
- FDA Intervention: The FDA announced it would crack down on Hims, potentially restricting access to ingredients needed to manufacture Wegovy copycat pills, which would further weaken Hims' market capabilities and protect Novo Nordisk's market share.
- Litigation Progress: Novo Nordisk has filed a lawsuit in federal court seeking a permanent injunction against Hims selling any drugs that violate its '343 Patent, and if successful, could prohibit Hims from selling both Ozempic and Wegovy lookalikes, further solidifying Novo's market position.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
Bank of America Lowers Hims & Hers Price Target
- Price Target Reduction: Bank of America has lowered its price target for Hims & Hers, primarily due to FDA uncertainty and slowing GLP-1 sales, indicating market concerns regarding the company's future performance.
- Revenue Risk Warning: Analysts have highlighted that increasing uncertainty around FDA approvals may pose downside risks to Hims & Hers' revenue and profits, potentially impacting investor confidence.
- Uncertain Profit Outlook: Ahead of the upcoming earnings report, Bank of America expresses concerns over Hims & Hers' profit outlook, suggesting that the current market environment may lead to performance falling short of expectations.
- Market Reaction Anticipation: Given the price target reduction and warnings about profit risks, the market may react negatively to Hims & Hers' stock performance, prompting investors to carefully assess its future prospects.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
Hims & Hers Health Stock Faces Pressure Amid Regulatory Concerns
- Price Forecast Cut: BofA Securities has lowered the price target for Hims & Hers Health from $26 to $21 while maintaining an Underperform rating, indicating that the growing risks associated with GLP-1 sales could lead to a decline in future EBITDA multiples to 18.5x, highlighting increased market pressure on the company.
- Product Withdrawal Impact: Hims & Hers has decided to cease offering its compounded Semaglutide pill following accusations from Novo Nordisk of unlawful mass marketing of an unapproved drug, which may diminish the company's competitiveness in the weight loss market and negatively affect future revenues.
- Revenue Outlook Downgrade: BofA estimates that Hims & Hers will generate $825-$850 million in injectable GLP-1 sales for fiscal 2025 at approximately 10% EBITDA margins, while the management has narrowed its fiscal 2025 revenue outlook to a range of $2.335 billion to $2.355 billion, reflecting market concerns over its performance.
- Significant Stock Volatility: As of Monday, Hims shares are down 18.77% at $18.70, indicating investor anxiety regarding the company's future performance, particularly in light of potential FDA restrictions on GLP-1 active pharmaceutical ingredients, leading to heightened market caution.
See More
Hims & Hers Shares Plunge to New 52-Week Lows Amid Legal and Regulatory Challenges
- Stock Plunge: Hims & Hers shares fell to new 52-week lows on Monday, dropping 20.10% to $18.39, indicating severe market concerns regarding the company's growth prospects.
- Regulatory Pressure: The company announced it would cease sales of its compounded oral semaglutide pill just 48 hours after launch, highlighting significant challenges in its market strategy under intense FDA and DOJ scrutiny.
- Patent Lawsuit: Novo Nordisk filed a patent infringement lawsuit on Monday, exacerbating Hims & Hers' legal troubles and raising doubts among investors about the profitability of its new product line.
- Surge in Trading Volume: On Monday, Hims & Hers experienced trading volume exceeding four times its average, reflecting strong investor reactions to the uncertainty surrounding the company's future, leading to significant sell-offs.
See More
Novo Nordisk Stock Rebounds as Hims Abandons Copycat Drug Plans
- Stock Volatility: Novo Nordisk's shares plummeted 27% last week due to Hims' plan to sell a $49 copy of Wegovy, but rebounded 3% after Hims announced it would not proceed with the sale, indicating a restoration of market confidence in Novo's products.
- Legal Threat: Novo Nordisk expressed strong dissatisfaction with Hims' copycat plans and threatened to sue for patent infringement last Friday, demonstrating the company's firm stance on protecting its intellectual property, which could impact Hims' competitive position in the market.
- FDA Intervention: The FDA announced it would crack down on Hims, potentially restricting access to ingredients needed to manufacture Wegovy copycat pills, which would further weaken Hims' market capabilities and protect Novo Nordisk's market share.
- Litigation Progress: Novo Nordisk has filed a lawsuit in federal court seeking a permanent injunction against Hims selling any drugs that violate its '343 Patent, and if successful, could prohibit Hims from selling both Ozempic and Wegovy lookalikes, further solidifying Novo's market position.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
